The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors

Witold Owczarek; Monika Słowińska; Aleksandra Lesiak; Magdalena Ciążyńska; Aldona Maciąg; Elwira Paluchowska; Luiza Marek-Józefowicz; Rafał Czajkowski

doi:10.5114/ada.2017.71106

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2017
vol. 34

Send email

Copy url:

abstract:

Review paper

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors

Witold Owczarek

,

Monika Słowińska

,

Aleksandra Lesiak

,

Magdalena Ciążyńska

,

Aldona Maciąg

,

Elwira Paluchowska

,

Luiza Marek-Józefowicz

,

Rafał Czajkowski

Adv Dermatol Allergol 2017; XXXIV (5): 418–428

DOI: https://doi.org/10.5114/ada.2017.71106

Online publish date: 2017/10/31

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Owczarek W, Słowińska M, Lesiak A, et al. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2017;34(5):418-428. doi:10.5114/ada.2017.71106.

APA

Owczarek, W., Słowińska, M., Lesiak, A., Ciążyńska, M., Maciąg, A.,  & Paluchowska, E. et al. (2017). The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 34(5), 418-428. https://doi.org/10.5114/ada.2017.71106

Chicago

Owczarek, Witold, Monika Słowińska, Aleksandra Lesiak, Magdalena Ciążyńska, Aldona Maciąg, Elwira Paluchowska,  and Luiza Marek-Józefowicz et al. 2017. "The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 34 (5): 418-428. doi:10.5114/ada.2017.71106.

Harvard

Owczarek, W., Słowińska, M., Lesiak, A., Ciążyńska, M., Maciąg, A., Paluchowska, E., Marek-Józefowicz, L.,  and Czajkowski, R. (2017). The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 34(5), pp.418-428. https://doi.org/10.5114/ada.2017.71106

MLA

Owczarek, Witold et al. "The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 34, no. 5, 2017, pp. 418-428. doi:10.5114/ada.2017.71106.

Vancouver

Owczarek W, Słowińska M, Lesiak A, Ciążyńska M, Maciąg A, Paluchowska E et al. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2017;34(5):418-428. doi:10.5114/ada.2017.71106.

Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them. The mechanism through which skin toxicity arises during treatment with EGFR inhibitors is not well known, but seems to be due to the modification of the RAS/RAF/MEK/ERK signal path associated with its activation, which results in the similarity between the adverse effects of EGFR inhibitors and the treatment of melanoma with BRAF and MEK inhibitors. The most common side effects are pruritus, xerosis, papulopustular rash, hand-foot skin reaction, alopecia and dystrophy of the hair, and paronychia. This work presents options for prevention and suggestions for managing these adverse events, which are of importance in the care of patients undergoing oncological treatment.

keywords:

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors

Witold Owczarek , Monika Słowińska , Aleksandra Lesiak , Magdalena Ciążyńska , Aldona Maciąg , Elwira Paluchowska , Luiza Marek-Józefowicz , Rafał Czajkowski

EGFR inhibitor, dermatological adverse effects, BRAF inhibitor, MEK inhibitor

Witold Owczarek

,

Monika Słowińska

,

Aleksandra Lesiak

,

Magdalena Ciążyńska

,

Aldona Maciąg

,

Elwira Paluchowska

,

Luiza Marek-Józefowicz

,

Rafał Czajkowski